HOME >> BIOLOGY >> NEWS
When One Gene Has Two Roles, Its Second Function May Be Missed

these are clearly the most distant regulatory elements that have been identified in any structural gene. It's a further demonstration of why we need to map and sequence the entire genome if we hope to understand how these elements work."

Derangements of GATA-2 expression could underlie any of a wide range of human conditions. The researchers note that developmental abnormalities of the genitourinary system are estimated to affect 10 percent of the population, accounting for one-third of all congenital malformations and 40 percent of kidney diseases.

The researchers also note that the general approach of trying to replace a missing function in mice that have had a gene knocked out may reveal unknown functions of that gene at later developmental stages.

Other authors on the EMBO Journal paper include graduate student Yinghui Zhou and postdoctoral fellows Kim-Chew Lim and Ko Onodera, all of Northwestern; Stuart H. Orkin, Leland Fikes Professor of Pediatric Medicine, and postdoctoral researcher Fong-Ying Tsai of Harvard Medical School; and Masayuki Yamamoto, professor of molecular and developmental biology, and postdoctoral researchers Satoru Takahashi, Naoko Minegishi and Jun Ohta of the University of Tsukuba.

The research was funded by the National Institute of General Medical Sciences, one of the National Institutes of Health.


'"/>

Contact: Bill Burton
b-burton@nwu.edu
847-491-3115
Northwestern University
12-Nov-1998


Page: 1 2 3

Related biology news :

1. Second call for proposals for the European Young Investigator Award
2. Second generation targeted antibodies - Its all in the binding
3. Secondary complications and restoration of function in SCI
4. Second EMBO International Practical Workshop for Science Teachers
5. NTP-CERHR announces the Second Phthalates Expert Panel Meeting to be held December 15-17, 1999
6. In Logged Forests, Hunting of Wildlife Becomes Deadly Second Harvest
7. Iron Supplemented Formula Milk Should Be Free For Inner City Children Into Their Second Year Of Life
8. Oregon Scientists Discover A Second Blood-Brain Barrier; Important Finding For Patients With Brain Cancers And Neurological Disorders
9. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
10. The Second Visible Human Project Conference
11. Researchers Take A Second Look At Homocysteines Link To Heart Disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: When One Gene Has Two Roles Its Second Function May Missed

(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, a ... Internet of Things (IoT), today announced the appointment of ... operating officer. Previously a strategic advisor to the firm, ... operations. Mr. Traynor is based out of the C-Labs ... reports to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 ... today that it has entered into a technology ... Company (ADM) to apply DNA2.0’s proprietary protein engineering ... engineering process. , “We are extremely excited that ... engineering platform. This proprietary bioengineering technology has ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
Cached News: